RAPT Therapeutics, Inc.
RAPT
$0.906
-$0.0151-1.64%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 28.88M | 27.33M | 27.78M | 27.81M | 26.06M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 136.10M | 114.85M | 128.98M | 128.02M | 127.06M |
| Operating Income | -136.10M | -114.85M | -128.98M | -128.02M | -127.06M |
| Income Before Tax | -129.87M | -107.49M | -120.43M | -118.05M | -116.80M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -129.87 | -107.49 | -120.43 | -118.05 | -116.80 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -129.87M | -107.49M | -120.43M | -118.05M | -116.80M |
| EBIT | -136.10M | -114.85M | -128.98M | -128.02M | -127.06M |
| EBITDA | -134.90M | -113.61M | -127.72M | -126.79M | -125.85M |
| EPS Basic | -3.12 | -2.78 | -3.12 | -3.07 | -3.05 |
| Normalized Basic EPS | -1.97 | -1.77 | -1.99 | -1.96 | -1.95 |
| EPS Diluted | -3.12 | -2.78 | -3.12 | -3.07 | -3.05 |
| Normalized Diluted EPS | -1.97 | -1.77 | -1.99 | -1.96 | -1.95 |
| Average Basic Shares Outstanding | 163.08M | 154.78M | 154.23M | 153.70M | 153.35M |
| Average Diluted Shares Outstanding | 163.08M | 154.78M | 154.23M | 153.70M | 153.35M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |